Dr. Lal Pathlabs Limited — Capital/Financing Update 2019

Apr 1, 2019

==> picture [45 x 21] intentionally omitted <==

==> picture [288 x 41] intentionally omitted <==

April 1, 2019

National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Dalal Street Sandra (E) Mumbai- 400001 Mumbai - 400 051.

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company's wholly owned subsidiary Pathlabs Unifiers Private Limited, at their meeting held on Monday, April 1, 2019 approved, acquisition of a Proprietorship Concern. i.e. "M/s Bawankar Pathology".

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the Annexure I attached to this letter.

We request you to kindly take the same on record.

Thanking You,

==> picture [202 x 120] intentionally omitted <==

----- Start of picture text -----

Yours faithfully,
\ila6
o r Lal Pathl. a � dffiited'
� m \
' � • -1 • ~ -·
Q)
)
/
ijatK Ira
Company Secretary and Legal Head
Encl.: As above
0 q,
----- End of picture text -----*

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector- I 8, Rohini, New Delhi - 110085, ( +91-11-30258600, Fax: +9 I -11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12th Fl oor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122 001, Haryana .(. +91-124-3016-500, Fax: +91-124-4234-468 E-mail: lal pathlabs@lalQathlabs.com, Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388

__ _,

Annexure I

Sr. No.	Particulars in respect of the Event			Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc. Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";			Name: M/s Bawankar Pathology Turnover:As detailed in Point No. 10 No, the transactionis not arelated party transaction.
2.
3.	Industrto which the entity beinq acquired belonqs.			Healthcare/ Diaqnostics
4.	Objects and efects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);			The Company's Subsidiary Pathlabs Unifiers Private Limited has decided to acquire100% of business of M/s Bawankar Pathology with the objective of strengthening its presence in the business.
5.	Briefdetailsofany governmentalorregulatory approvals required fr the acquisition			No government approvals required
6. 7.	Indicative time period fr completion of the acquisition Nature of consideration - whether cash consideration or share swap and details of the same			Within 3 month
				Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired			Not exceedingINR5.20 Crores
9.	Percentage of shareholding / control acquired and / or number of shares acquired;			Complete Control
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information			M/s Bawankar Pathology isa sole- proprietorship firm based out of Bhandara, Maharashtra. Audited turnover for M/sBawankar Pathology for the last three financial years (Amount in INR Crores): FY16- INR 1 Cr. FY17 - INR 1.3 Cr FY18 - INR 1.5 Cr.

==> picture [104 x 80] intentionally omitted <==